Now more than ever there are many options for treating patients with inflammatory bowel disease (IBD). Whether it is ustekinumab, upadacitinid, mirikizumab, or the many other biologics available, there are options for patients with either Crohn’s disease or ulcerative colitis. But how do doctors decide which medicine is right for which patient and what happens when that patient doesn’t respond? While complicated, the many options available could eventually result in something that has proven to be elusive in medicine: a personalized approach for each patient. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more